This corresponded to a 1.8 ± 0.2-log tumor cell depletion of the PBPC product while 93.5 ± 2% of CD34+ cells and 81.0 ± 4.4% of PBPCs were retained as indicated by relative center fraction recovery rates of 6.5 ± 2% and 19.0 ± 4.4% for CD34+ cells and PBPCs, respectively (n = 2, mean ± SD, Fig. 3, left panel). This evidence concerns the gene CD34 and neoplasm.